Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Khandan Keyomarsi

Showing results (51-60 of 105) with videos related to

Pageof 11
Sort By:
Investigational New Drugs|May 8, 2015
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancerZahi Mitri, Cansu Karakas, Caimiao Wei, et al.
Cell Cycle (Georgetown, Tex.)|July 25, 2006
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathwayXiao-Feng Le, Isabelle Bedrosian, Weiqun Mao, et al.
Science Translational Medicine|December 24, 2025
Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenograftsXiao-Ting Jiang, Mei-Kuang Chen, Jiwang Lee, et al.
Cancer Research|May 6, 2004
Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancerSaid Akli, Ping-Ju Zheng, Asha S Multani, et al.
Molecular Cancer Therapeutics|January 31, 2016
Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerNatalie A Jabbour-Leung, Xian Chen, Tuyen Bui, et al.
Breast Cancer Research : BCR|January 1, 2015
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrenceJoseph A Caruso, Cansu Karakas, Jing Zhang, et al.
Breast Cancer Research : BCR|June 26, 2015
Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrenceJoseph A Caruso, Cansu Karakas, Jing Zhang, et al.
Plos Genetics|April 6, 2012
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patientsMyLinh T Duong, Said Akli, Caimiao Wei, et al.
Cell Cycle (Georgetown, Tex.)|March 24, 2009
Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progressionHannah Wingate, Agnes Puskas, Mylinh Duong, et al.
The American Journal of Pathology|May 17, 2016
Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerCansu Karakas, Anna Biernacka, Tuyen Bui, et al.
Pageof 11

Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Investigational New Drugs|May 8, 2015
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancerZahi Mitri, Cansu Karakas, Caimiao Wei, et al.
Cell Cycle (Georgetown, Tex.)|July 25, 2006
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathwayXiao-Feng Le, Isabelle Bedrosian, Weiqun Mao, et al.
Science Translational Medicine|December 24, 2025
Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenograftsXiao-Ting Jiang, Mei-Kuang Chen, Jiwang Lee, et al.
Cancer Research|May 6, 2004
Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancerSaid Akli, Ping-Ju Zheng, Asha S Multani, et al.
Molecular Cancer Therapeutics|January 31, 2016
Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast CancerNatalie A Jabbour-Leung, Xian Chen, Tuyen Bui, et al.
Breast Cancer Research : BCR|January 1, 2015
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrenceJoseph A Caruso, Cansu Karakas, Jing Zhang, et al.
Breast Cancer Research : BCR|June 26, 2015
Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrenceJoseph A Caruso, Cansu Karakas, Jing Zhang, et al.
Plos Genetics|April 6, 2012
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patientsMyLinh T Duong, Said Akli, Caimiao Wei, et al.
Cell Cycle (Georgetown, Tex.)|March 24, 2009
Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progressionHannah Wingate, Agnes Puskas, Mylinh Duong, et al.
The American Journal of Pathology|May 17, 2016
Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerCansu Karakas, Anna Biernacka, Tuyen Bui, et al.
Pageof 11